RxDoctor Payments Data

Ryan Melvin, DO

Cardiovascular Disease · Panama City, FLNPI 1679919724

Payments from drug & device makers

$10,044in general payments, 2019–2025

Across 94 payments — averaging $106.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$6K
  • Abbott$2K
  • Boston Scientific$247
  • Novartis$204
  • AstraZeneca$166
  • Cardiovascular Systems Inc.$120
  • plus $601 from 12 others

What the payments were for

  • Consulting fees$6,35463%
  • Travel & lodging$1,73517%
  • Food & beverage$1,95519%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,044 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$11,488
Medicare patients
219
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$121,774
XareltoRivaroxaban37$38,099
EntrestoSacubitril/Valsartan29$33,112
Repatha SureclickEvolocumab16$11,901
Ranolazine ErRanolazine26$2,654
Rosuvastatin Calcium94$1,581
Carvedilol115$1,065
Metoprolol Succinate82$1,004
Atorvastatin Calcium96$861
Amiodarone Hcl27$531
Losartan Potassium55$526
Flecainide Acetate20$522
Ezetimibe37$429
Isosorbide Mononitrate ErIsosorbide Mononitrate32$384
Furosemide49$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$38,09937 claims
NovartisEntresto$204$33,11229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →